Industry News (Cervical Cancer)

Patent Allowed for Cervical Cancer Test

Published in Women's Health Weekly, January 18th, 1999

Matritech, Inc. announced that it has been notified by the U.S. Patent and Trademark Office that its patent application for the use of NMP179 -- which aids in the identification of and permits more effective management of women with cervical cancer or pre-cancerous conditions -- has been allowed.

When issued, the patent will grant protection to Matritech's NMP179^TM, a cell-based diagnostic test which differentiates cancerous and pre-cancerous cervical cells from normal cervical cells and may be used to predict the likelihood of disease progression.

"Cervical cancer is one of the most serious malignancies in women and frequently has fatal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1999-01-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry